Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from Chardan Capital

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a report released on Monday, Benzinga reports.

Other analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Wall Street Zen cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Finally, Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research note on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $256.00.

Gossamer Bio Trading Down 4.7%

GOSS stock traded down $0.45 during midday trading on Monday, reaching $9.15. 250,724 shares of the company’s stock traded hands, compared to its average volume of 241,172. The stock’s 50-day moving average is $11.48 and its 200 day moving average is $16.16. The stock has a market cap of $55.92 million, a P/E ratio of -0.16 and a beta of 2.21. Gossamer Bio has a 52-week low of $8.29 and a 52-week high of $309.60.

Institutional Trading of Gossamer Bio

A number of hedge funds and other institutional investors have recently modified their holdings of GOSS. Corient Private Wealth LP increased its stake in shares of Gossamer Bio by 41.3% in the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after purchasing an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC increased its stake in shares of Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after purchasing an additional 1,469,175 shares in the last quarter. Bank of America Corp DE purchased a new position in Gossamer Bio during the second quarter valued at $65,000. Hhlr Advisors LTD. purchased a new position in Gossamer Bio during the second quarter valued at $819,000. Finally, ARCH Venture Management LLC purchased a new position in Gossamer Bio during the second quarter valued at $1,326,004. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.